Subscribe To

Price Alert Latest News Economic Calendar News

OCUL / Next Round Of Financing Will Be Transformational For Ocular Therapeutix

Ocular Therapeutix is a promising platform play poised to disruptively transform ophthalmology. Based on its innovative and validated hydrogel platform, Ocular can fill and expand its pipeline with unlimited new applications. With Dextenza, Ocular has an approved and profitable commercial product and is confident that its new strategy will accelerate its growth in 2023. Read More

Demo Live Account See Partner Details

Content Topics

Round

Financing

Will

Transformational

Ocular

Therapeutix

Stock

OCUL

Posted: Feb 14 2023, 09:01

Author Name: Seeking Alpha

OCUL News

By Zacks Investment Research
August 7, 2023

Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to l

By GlobeNewsWire
June 5, 2023

Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting

BEDFORD, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve

By Seeking Alpha
May 8, 2023

Ocular Therapeutix, Inc. (OCUL) Q1 2023 Earnings Call Transcript

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q1 2023 Results Conference Call May 8, 2023 4:30 PM ET Company Participants Donald Notman - Chief Financial Of

By Zacks Investment Research
May 8, 2023

Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to l

By GlobeNewsWire
April 14, 2023

Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

BEDFORD, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, dev

By Zacks Investment Research
March 8, 2023

What Makes Ocular Therapeutix (OCUL) a Good Fit for 'Trend Investing'

Ocular Therapeutix (OCUL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound st

By Seeking Alpha
March 6, 2023

Ocular Therapeutix, Inc. (OCUL) Q4 2022 Earnings Call Transcript

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Donald Notman - Chief Financial

By Zacks Investment Research
March 6, 2023

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 4% and 3.50%, respectively, for the quarter ended December 2022. Do the numbers

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.